Dyne Therapeutics Inc Cash Flow Conversion Efficiency
Dyne Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Dyne Therapeutics Inc (DYN) has a cash flow conversion efficiency ratio of -0.168x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-144.92 Million) by net assets ($865.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Dyne Therapeutics Inc (2007–2025)
Cash flow conversion efficiency of Dyne Therapeutics Inc from 2007 to 2025. This chart illustrates how Dyne Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DYN stock price for real-time trading data and today's change.
Dyne Therapeutics Inc Cash Flow Conversion Ratio Explained
Dyne Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dyne Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dyne Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Dyne Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
0.052x |
|
Theon International Plc
AS:THEON
|
0.016x |
|
Clearway Energy Inc Class C
NYSE:CWEN
|
0.030x |
|
Ambarella Inc
NASDAQ:AMBA
|
0.032x |
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
0.059x |
|
Steadfast Group Limited
F:1S6
|
0.055x |
|
Novoray Corporation
SHG:688300
|
0.057x |
|
Liberty Energy Inc.
NYSE:LBRT
|
0.068x |
Annual Cash Flow Conversion Efficiency for Dyne Therapeutics Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Dyne Therapeutics Inc from 2007 to 2025. Review DYN free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $972.13 Million | $-403.21 Million | -0.415x | +10.65% |
| 2024-12-31 | $629.84 Million | $-292.37 Million | -0.464x | +77.48% |
| 2023-12-31 | $91.29 Million | $-188.16 Million | -2.061x | -238.53% |
| 2022-12-31 | $252.36 Million | $-153.65 Million | -0.609x | -87.49% |
| 2021-12-31 | $368.20 Million | $-119.56 Million | -0.325x | -139.05% |
| 2020-12-31 | $342.37 Million | $-46.51 Million | -0.136x | +83.89% |
| 2019-12-31 | $14.04 Million | $-11.83 Million | -0.843x | -198.79% |
| 2018-12-31 | $-4.88 Million | $-4.16 Million | 0.853x | +177.34% |
| 2017-12-31 | $1.90 Billion | $585.00 Million | 0.308x | -7.04% |
| 2016-12-31 | $2.04 Billion | $676.00 Million | 0.331x | +928.71% |
| 2015-12-31 | $2.92 Billion | $94.00 Million | 0.032x | +256.91% |
| 2014-12-31 | $3.02 Billion | $-62.00 Million | -0.021x | -125.90% |
| 2013-12-31 | $2.21 Billion | $175.00 Million | 0.079x | +550.46% |
| 2012-12-31 | $2.50 Billion | $-44.00 Million | -0.018x | +2.26% |
| 2011-12-31 | $1.11 Billion | $-20.00 Million | -0.018x | -111.68% |
| 2010-12-31 | $2.75 Billion | $423.00 Million | 0.154x | +239.92% |
| 2009-12-31 | $2.98 Billion | $135.00 Million | 0.045x | -36.29% |
| 2008-12-31 | $4.49 Billion | $319.00 Million | 0.071x | -5.53% |
| 2007-12-31 | $4.53 Billion | $341.00 Million | 0.075x | -- |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more